#Singapore #Clinical Trials #George Clinical #Emerald Clinical

Emerald Clinical Trials: A New Identity for Global Clinical Research

In an exciting development for the clinical research industry, George Clinical, a prominent global contract research organization (CRO), has officially changed its name to Emerald Clinical Trials. This rebranding, announced on April 7, 2025, represents not just a change of name, but a strategic shift emphasizing the company’s commitment to transparency and innovation in clinical research.

A Reflection of Growth

Emerald Clinical Trials reflects the company's growth and the enhanced level of service it brings to global trial landscapes. The transition underscores the organization’s commitment to delivering reliable, consistent, and flexible clinical research solutions. With over two decades of experience, Emerald has positioned itself as a diligent partner, helping reduce risks involved in clinical development through its therapeutic and regional expertise.

CEO Mary Gunn stated, "Emerald Clinical Trials has been focused on delivering high-quality trials, combining global reach with local insights over the last two decades. Our rebranding reinforces our dedication to our values and client commitments while enhancing our position as a trusted partner in clinical research." The new name also amplifies the firm’s message about its commitment to excellent patient care and solid relationships with clients and collaborators.

Comprehensive Services Across Therapeutic Areas

Emerald Clinical Trials maintains a robust portfolio, offering end-to-end services across various therapeutic domains. With a particular emphasis on oncology and cardio-metabolic diseases, the company leverages its recognized expertise in the Asia-Pacific region and its globally admired scientific leadership.

Operating directly in 42 countries and fostering partnerships in 70 nations, Emerald ensures that clinical trials are executed seamlessly worldwide. The scale of operations allows them to adapt quickly to the needs of the biopharmaceutical industry, whether clients are emerging biotech firms or leading pharmaceutical corporations.

Commitment to Client-Centered Practices

Emerald's rebranding highlights its strong commitment to customer-centric practices. This approach nurtures long-term relationships based on trust and measurable success. Through their dedicated service, they assure clients of predictable trial outcomes, as evidenced by client loyalty and numerous industry excellence awards.

Dr. Daniel Tillett, CEO of Race Oncology, a satisfied client of Emerald, noted, “We decided early on to collaborate with a CRO that offered flexible approaches tailored to the unique needs of each study. The agility provided by Emerald is essential for biopharmaceutical companies that need a partner capable of pivoting alongside them without the bureaucratic inefficiencies that can often delay progress.”

The Bright Future of Emerald Clinical Trials

Emerald Clinical Trials is committed to shaping the future of clinical research. As a prominent CRO serving over 100 biotechnology firms and six of the largest pharmaceutical companies, the company is poised to lead the charge in advancing clinical innovations. Their operational excellence and scientific expertise enable them to support clients through every phase of a clinical trial, ensuring comprehensive solutions tailored to meet specific objectives.

As the organization embarks on this new chapter as Emerald Clinical Trials, they invite stakeholders to join them in transforming the clinical research landscape for better patient outcomes globally. To learn more, visit Emerald Clinical Trials.

For media inquiries, please contact Shannon Severino at [email protected] or call (+1) 412 608 2393.